Performance-based managed entry agreements for new medicines in OECD countries and EU member states: How they work and possible improvements going forward

Martin Wenzl and Suzannah Chapman
Additional contact information
Martin Wenzl: OECD
Suzannah Chapman: OECD

No 115, OECD Health Working Papers from OECD Publishing

Abstract: This paper presents findings of an OECD review of managed entry agreements in OECD countries and EU member states conducted in 2018 and 2019. Findings are based on discussions with the OECD Expert Group on Pharmaceuticals and Medical Devices, responses by experts from 12 OECD countries to a survey and semi-structured interviews, and on the literature as well as information published by national authorities responsible for coverage and pricing of medicines.

JEL-codes: H51 I11 I13 O32 O38 (search for similar items in EconPapers)
Date: 2019-12-19
New Economics Papers: this item is included in nep-ore and nep-sbm
References: Add references at CitEc
Citations: View citations in EconPapers (9)

Downloads: (external link)
https://doi.org/10.1787/6e5e4c0f-en (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:oec:elsaad:115-en

Access Statistics for this paper

More papers in OECD Health Working Papers from OECD Publishing Contact information at EDIRC.
Bibliographic data for series maintained by ().